ARWR - CIK 0000879407
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported revenue of $829.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $829.45M | +23258.2% |
| FY 2024 | $3.55M | -98.5% |
| FY 2023 | $240.74M | -1.0% |
| FY 2022 | $243.23M | +75.9% |
| FY 2021 | $138.29M | +57.2% |
| FY 2020 | $87.99M | -47.9% |
| FY 2019 | $168.80M | +945.7% |
| FY 2018 | $16.14M | -48.6% |
| FY 2017 |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported revenue of $829.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ARROWHEAD PHARMACEUTICALS, INC.'s revenue grew from $296.14K to $829.45M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $31.41M |
| +19736.5% |
| FY 2016 | $158.33K | -58.6% |
| FY 2015 | $382.00K | +118.3% |
| FY 2014 | $175.00K | -39.7% |
| FY 2013 | $290.27K | +97.6% |
| FY 2012 | $146.88K | -50.4% |
| FY 2011 | $296.14K | - |